Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Could SL1009 Ease the Ketogenic Diet for Children With PDCD? What Its Trial's Ketone Numbers Show Before December 30th

Saol's SL1009 for PDCD faces an FDA decision by December 30, 2026. In its trial, ketones rose slightly but not significantly on the drug, and its authors suggested some children might manage a lower-ratio diet. A liver gene test set each child's dose.

An avocado cut in half with its pit showing, leaning against a whole avocado on a white surface.

Harlow Higbee was diagnosed with pyruvate dehydrogenase complex deficiency after nearly a year of tests, and for a time her only treatment was a strict ketogenic diet. After she joined the University of Florida trial of dichloroacetate, her mother wrote that the drug let the family ease back on that diet (Higbee, 2025).

That one line speaks to many PDCD families, since the diet is the main treatment and one of the hardest parts of the day. The FDA is due to decide on SL1009, the version of dichloroacetate now under review, by December 30, 2026. Its published Phase 3 trial holds ketone numbers that families rarely see next to the targets their dietitians aim for, and this post puts them side by side.

What Is SL1009, and When Will the FDA Decide on It for PDCD?

SL1009 is an oral liquid form of sodium dichloroacetate (DCA) made by Saol Therapeutics. The FDA's goal date for deciding on it in pyruvate dehydrogenase complex deficiency is December 30, 2026, and an approval would make it the first FDA-approved medicine for PDCD (Saol, July 2026).

Saol's first application was turned down on August 27, 2025, when the FDA said it did not show enough evidence that the drug works (FDA, 2025). The letter asked for at least 1 new well-controlled trial. Saol says that at later meetings the FDA advised more survival analyses instead, and it resubmitted on June 30, 2026 without a new trial (Saol, July 2026). The FDA accepted the resubmission as a complete Class 2 response and set the December 30 goal date. The full record of what the FDA's letter said is on Trial Friend's SL1009 page, and the SL1009 decision page will change the day the FDA acts.

In PDCD, a gene change leaves the pyruvate dehydrogenase complex weak, so cells cannot fully turn sugar into energy and make lactic acid instead. DCA blocks the brake on that complex, an enzyme called pyruvate dehydrogenase kinase. Whatever working complex a child has then stays switched on more of the time (Stacpoole et al., 2026).

Why the Ketogenic Diet Is the Main PDCD Treatment, and Why It Is Hard to Keep

A ketogenic diet gives the brain a fuel that skips the broken step. The body turns fat into ketones, which cross into the brain and give its cells an energy source that bypasses the broken pyruvate dehydrogenase complex (Hope for PDCD Foundation). The main ketone doctors measure in blood is beta-hydroxybutyrate.

Families talk about the diet as a ratio of fat to carbohydrate plus protein. In the SL1009 trial, 24 of 34 children were on a ketogenic diet when it began, and their ratios mostly ran between 2.5:1 and 4.1:1 (Stacpoole et al., 2026). Diet ratios are usually counted by weight, and on a classic 4:1 diet that works out to about 90% of calories from fat. The trial paper described its ratios in terms of calories, so its numbers may not line up with a family's own.

Many children do well on the diet, and a Swedish study shows where. The 19 children with PDCD in it were treated for a median of 2.9 years. The diet helped most with seizures, balance, sleep, speech and social skills, and it meant fewer hospital stays (Sofou et al., 2017).

“Treatment effect was mainly determined by disease phenotype and attainment and maintenance of ketosis.”

Sofou et al., Journal of Inherited Metabolic Disease, 2017

Staying in ketosis day after day is the hard part. In the Swedish group, the 2 children who had trouble keeping to the diet saw their balance problems return and their development stall. One child stopped the diet because of pancreatitis (Sofou et al., 2017). Harlow's mother wrote that the high fat content often upset her daughter's stomach.

Researchers have questioned the evidence behind the diet too. A 2001 review by Peter Stacpoole's University of Florida group found that the diets used for PDCD varied widely, and the same group later led the SL1009 trial. The authors called for a controlled study of the diet's risks and benefits (Weber et al., 2001).

Free email alert

Email me the day the FDA decides on SL1009

One email when the decision is public, with what it means in plain language, plus new trials and FDA news for Pyruvate Dehydrogenase Complex Deficiency. Unsubscribe anytime.

You'll get trial alerts and disease updates for Pyruvate Dehydrogenase Complex Deficiency, and you can turn either off anytime. We never share your email. Privacy policy

What SL1009 Did to Ketone Levels in the Phase 3 Trial

Ketone levels rose slightly on SL1009 in the Phase 3 trial. Among the 24 children keeping to a ketogenic diet, average beta-hydroxybutyrate started at 2.7mmol/L (Stacpoole et al., 2026). It was 3.0mmol/L after 4 months of SL1009 and 2.3mmol/L after 4 months of placebo.

Blood ketones in the SL1009 trial, set against the PDCD ketone target
Ketones here are blood beta-hydroxybutyrate in mmol/L. The shaded target of 3 to 5 is the range the trial paper cites for children with PDCD on a ketogenic diet, and a UCSF ketogenic dietitian writing for the Hope for PDCD Foundation calls 3 to 4.5 ideal. Values are averages for the 24 children keeping to the diet, each measured at the start and at the end of 4-month periods on SL1009 and on placebo.
Start of the trial
SL1009-01, 24 children on the diet
2.7 average
After 4 months of placebo
Same 24 children
2.3 average
After 4 months of SL1009
Same 24 children
3.0 average
Before either treatmentOn placeboOn SL1009

On average, children keeping to the ketogenic diet in the SL1009 trial began just under the 3mmol/L floor of their target range, reached that floor after 4 months of SL1009 and fell further below it after 4 months of placebo. Trial Friend set the trial's published averages (Stacpoole et al., 2026) against the target range the same paper cites, checked November 21, 2026. The paper describes the rise on SL1009 as not statistically significant.

The paper describes that rise as not statistically significant, and across all 34 children the difference was 0.44mmol/L, which chance could explain. The rise leveled off in most children and did not appear to keep climbing after more than 12 months of treatment. No child had ketoacidosis, a dangerous buildup of acid in the blood (Stacpoole et al., 2026).

The trial's authors tie the rise to the drug's own action. They wrote that by turning more pyruvate into acetyl-CoA, the step just past the broken one, DCA would lead to more beta-hydroxybutyrate being made.

Could SL1009 Let a Child With PDCD Eat More Carbohydrate?

Nobody knows yet, because no study has tested it. The Phase 3 trial measured motor scores, lactate, seizures and survival rather than whether children could safely eat differently on the drug (Stacpoole et al., 2026).

The idea comes from the trial's own authors. Because SL1009 nudged ketones up, they wrote that it is plausible the drug could let some children move to a lower-ratio diet. That would mean more of their calories from carbohydrate and protein (Stacpoole et al., 2026).

That suggestion rests on a rise that was not statistically significant. Saol helped fund the study, and the paper lists authors with ties to Saol or to Medosome Biotec, which makes the dosing test. Saol also said in September 2026 that it had received notice of an allowed patent covering giving SL1009 to patients who follow a ketogenic diet (Saol, September 2026).

“with DCA we've been able to ease back and make her nutrition more tolerable”

Kim Higbee, whose daughter Harlow took DCA in the trial, writing in Patient Worthy, October 2025

One family's experience is a reason to study the question, not an answer to it. Lactate is the other number families watch, and average plasma lactate was 0.48mmol/L lower on SL1009 than on placebo, about 20%. During the open-label period, 23 of the 30 children with data stayed under the normal limit of 2.0mmol/L (Stacpoole et al., 2026).

Regulators read the lactate result more cautiously, and the FDA's 2025 letter called the changes from the starting level minimal. It said the data did not show that a lower lactate predicts real benefit in PDCD (FDA, 2025).

A family wondering whether SL1009 might change their child's diet can bring the numbers a metabolic team would weigh to the next visit. Those are recent ketone and lactate readings, the current diet ratio, and how often illness has knocked the child out of ketosis.

How a Liver Gene Called GSTZ1 Sets the SL1009 Dose

Each child's SL1009 dose depends on a gene test as well as on weight. The liver breaks DCA down with an enzyme made by the GSTZ1 gene. People with at least 1 copy of a version called EGT clear the drug faster (Stacpoole et al., 2026).

EGT is the most common version, making up 45-55% of GSTZ1 copies across ethnic groups, while a slow version called KRT makes up under 10% in many populations. In the trial, children with an EGT copy took 12.5mg/kg every 12 hours from a 50mg/mL liquid. Children without one took half that dose, 6.25mg/kg every 12 hours (Stacpoole et al., 2026).

DCA also slows its own breakdown, because it switches off the enzyme that clears it. A University of Florida dosing model found that effect is 25 to 30 times weaker in children than in adults (Mangal et al., 2018). In 17 children treated long term, drug levels varied 3 to 6 times by gene type but leveled off rather than building up (Shroads et al., 2015).

Nerve damage in the hands and feet is the drug's main known risk. A 2006 trial in people aged 10 to 60 with MELAS, a different mitochondrial disease, was stopped early because of it at 25mg/kg a day for everyone, without gene testing (Kaufmann et al., 2006). In the PDCD trial, where doses were set by gene type, no child had reported neuropathy during the blinded part, though nerve conduction tests were not done. One 17.5-year-old developed mild neuropathy after 18 months of open-label treatment, and the authors rated it possibly related to the drug (Stacpoole et al., 2026).

If approved, SL1009 would be prescribed alongside a dose-setting genetic test from Medosome Biotec, according to Saol (Saol, July 2026). The approved label, not the trial, would set the final doses.

Two PDCD Children, Same SL1009 Dose, Worked From the Trial's Rules

These 2 children are made-up examples rather than real patients, built from the trial's published dosing rules to show how the gene test changes the math. An approved label could set different doses for real children.

Mia, age 3, 14kg, 1 EGT copy
12.5mg/kg twice a day, 175mg or 3.5mL each time
Mia gets a 4:1 keto formula through a feeding tube, and her home ketone readings usually sit near 3mmol/L, the bottom of her target range. The trial's average rise was small and not statistically significant, so no one can predict what Mia's ketones would do on SL1009. Any question about her diet ratio would be for her metabolic team.
Noah, age 9, 28kg, no EGT copy
6.25mg/kg twice a day, also 175mg or 3.5mL each time
Noah eats a food-based modified keto diet and weighs twice as much as Mia. He would still get the same dose, because his liver clears DCA more slowly. Gene-guided dosing is meant to keep his drug levels from running high, which matters because nerve damage in the hands and feet is the drug's main known risk.

A 14kg child and a 28kg child landing on the same 175mg dose shows why SL1009 comes with a gene test. Trial Friend worked these figures from the trial's published doses and its 50mg/mL strength (Stacpoole et al., 2026), checked November 21, 2026.

Gene Therapy, Newborn Screening and the PDCD Research Beyond SL1009

The outlook for children with PDCD is brighter than it was a few years ago, though most of the progress beyond SL1009 is still in the lab. Gene therapy draws the most hope, because 80-88% of cases come from a single gene, PDHA1 (Hope for PDCD Foundation). That gene is small enough to fit inside the viruses used to carry gene therapies.

A 2026 study from University College London gave newborn mice a single dose of a newer brain-targeting virus carrying PDHA1. It improved their survival and brought their enzyme activity and brain tissue close to that of healthy mice (Keegan et al., 2026). Treated mice still had poorer coordination than healthy mice from about 30 days old through the end of the study at 100 days. No PDCD gene therapy study was listed on ClinicalTrials.gov when Trial Friend checked on November 21, 2026.

Families are paying for some of that work themselves. The Hope for PDCD Foundation says most of its donations go to Steven Gray's lab at UT Southwestern. That lab has completed a proof-of-concept study in mice on the way to a first human trial, according to the foundation. Its fundraiser is called the Butter Challenge, a nod to how much fat these children eat.

“Among rare diseases, Pyruvate Dehydrogenase Complex Deficiency is common.”

Rebecca Ganetzky, MD, Children's Hospital of Philadelphia, quoted by the Hope for PDCD Foundation

Earlier diagnosis matters too, according to the researchers working on newborn screening. A Pittsburgh team wrote in 2023 that age at diagnosis is the best predictor of survival and cognitive outcome in PDCD. In their records, certain amino acid ratios in blood caught all 13 patients with PDCD, while flagging about 15% of patients with other conditions by mistake (Verma et al., 2023).

In 2020, Ohio researchers looked back at newborn blood spots from 123,414 babies using an earlier amino acid ratio screen. It would have flagged all 3 babies diagnosed with PDCD that year, all girls with new PDHA1 changes, though it also flagged about 140 babies whose status was still unresolved (Bedoyan et al., 2020). PDCD is thought to affect about 1 in 40,000 babies born in the US (Stacpoole et al., 2026).

Two more medicines are in early trials for PDCD. Triheptanoin, a special fat already approved for long-chain fatty acid oxidation disorders, is being tested in up to 6 children in Pittsburgh with support from Ultragenyx (NCT06340685). Glycerol phenylbutyrate is being tested in up to 15 people aged 2 to 25 at Necker hospital in Paris (NCT06887777). Both were listed as recruiting when Trial Friend checked ClinicalTrials.gov on November 21, 2026.

Saol also announced up to $115 million in milestone-based financing from funds managed by Oaktree in September 2026 to prepare for a launch (Saol, September 2026). For families already on DCA through a study, approval would change the travel too. Tomas Hernandez told Arizona's Family that his family flies from Phoenix to Philadelphia so his daughter Elliana can take part. He said approval could let children get the medicine at local hospitals instead (Arizona's Family, 2026).

Until the FDA decides, a child's metabolic specialist can ask Saol about its expanded access program. ClinicalTrials.gov lists it for ages 0 to 17, though its criteria text says ages 0 through adulthood (NCT06931262, last verified May 2025). Open PDCD studies are listed on the PDCD trials page.

Email me the day the FDA decides on SL1009

One email when the decision is public, with what it means in plain language, plus new trials and FDA news for Pyruvate Dehydrogenase Complex Deficiency. Unsubscribe anytime.

You'll get, for Pyruvate Dehydrogenase Complex Deficiency:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

SL1009, DCA and Ketogenic Diet Questions PDCD Parents Ask

When will the FDA decide on SL1009 for PDCD?

The FDA's goal date for SL1009 in pyruvate dehydrogenase complex deficiency is December 30, 2026. Saol says the drug has Priority Review, Orphan Drug and Rare Pediatric Disease designations, and the FDA set the December 30 goal date for the June 2026 resubmission.

Does SL1009 replace the ketogenic diet?

No, SL1009 was tested alongside each child's usual care rather than instead of the diet. In the Phase 3 trial, 24 of 34 children were on a ketogenic diet when it began. Whether the drug could allow a looser diet has not been studied.

Why does SL1009 need a GSTZ1 gene test?

The GSTZ1 test shows how fast a child's liver clears DCA, so the dose can be cut in half for slower clearers. In the trial, children without an EGT copy of the gene took 6.25mg/kg every 12 hours instead of 12.5mg/kg, to keep drug levels from running too high.

Can girls get PDCD from the PDHA1 gene?

Yes, girls can have PDHA1-related PDCD even though the gene sits on the X chromosome. In the trial's survival comparison, 71.4% of the 28 matched children were girls. How severely a girl is affected depends partly on which X chromosome is active in her cells.

Can a child get SL1009 before FDA approval?

Possibly, through Saol's expanded access program, which ClinicalTrials.gov lists for ages 0 to 17. The request goes through the child's metabolic specialist, and the listing names AnovoRx as a collaborator.

Why did the FDA turn down SL1009 the first time?

The FDA's August 2025 letter said the application did not show substantial evidence that DCA works in PDCD. It noted the main motor score was not met. It also said differences between the groups meant a survival comparison with a 2012 natural history group could not show the drug works. It also asked for a heart rhythm study and a study of how food affects the drug.

Know someone this would help?

Sources

Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026
Saol Therapeutics via PR Newswire · 2026-07-28
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Saol Therapeutics via PR Newswire · 2026-07-07
Saol Therapeutics Announces Strategic Investment of Up to $115 Million from Oaktree to Support Launch Preparation for SL1009
Saol Therapeutics via PR Newswire · 2026-09-15
Complete Response Letter, NDA 218679, sodium dichloroacetate
U.S. Food and Drug Administration via openFDA · 2025-08-27
Phase III trial of sodium dichloroacetate for pyruvate dehydrogenase complex deficiency in children
JCI Insight (Stacpoole et al.) · 2026-09-22
Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes
Journal of Inherited Metabolic Disease (Sofou et al.) · 2017-03
Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency
Journal of Pediatrics (Weber, Antognetti and Stacpoole) · 2001-03
The Ketogenic Diet for PDCD
Hope for PDCD Foundation
PDCD Research: roadmap to a first in-human clinical trial for AAV9 gene replacement for PDHA1
Hope for PDCD Foundation
Hope for PDCD Foundation home page and FAQs
Hope for PDCD Foundation
Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children
Journal of Clinical Pharmacology (Mangal et al.) · 2018-02
Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children
Journal of Clinical Pharmacology (Shroads et al.) · 2015-01
Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial
Neurology (Kaufmann et al.) · 2006-02-14
Next generation AAV-F capsid gene therapy rescues disease pathology in a model of pyruvate dehydrogenase complex deficiency
Molecular Therapy Advances (Keegan et al.) · 2026-06-15
Amino acid ratio combinations as biomarkers for discriminating patients with pyruvate dehydrogenase complex deficiency from other inborn errors of metabolism
Molecular Genetics and Genomic Medicine (Verma et al.) · 2023-09
Utility of specific amino acid ratios in screening for pyruvate dehydrogenase complex deficiencies and other mitochondrial disorders associated with congenital lactic acidosis and newborn screening prospects
JIMD Reports (Bedoyan et al.) · 2020-08
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (NCT02616484)
ClinicalTrials.gov
Expanded Access Treatment Protocol With DCA for Patients With PDCD (NCT06931262)
ClinicalTrials.gov · 2026-11-21
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency (NCT06340685)
ClinicalTrials.gov · 2026-11-21
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (NCT06887777)
ClinicalTrials.gov · 2026-11-21
Opinion Piece: When the FDA Says No, Families Like Mine Lose More Than Medicine
Patient Worthy (Kim Higbee) · 2025-10-05
Arizona family finds hope in clinical trial drug for daughter's rare disease
Arizona's Family (KTVK/KPHO) · 2026-11-17
TaggedFDA DecisionsPyruvate Dehydrogenase Complex DeficiencySL1009Ketogenic Diet

More on Trial Friend